Patents by Inventor Joseph Christopher ELLIS

Joseph Christopher ELLIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11427860
    Abstract: Methods are disclosed for identifying antibacterial compounds which inhibit propagation of selected spectrum bacteria, which bacteria use specific tRNA to code for Ala, Met, Ser, or Leu that other bacteria do not use. In one embodiment, the selected spectrum bacteria use GCA to code for Ala, whereas other bacteria use a different codon to code for alanine. The methods involve determining whether putative inhibitors promote or inhibit complex formation between the tRNA and a bacterial ribosome, or between the tRNA and an aminoacyl synthetase. Compounds which promote or inhibit complex formation can disrupt protein production, which bacteria need to propagate. The identified antibacterial compounds can selectively inhibit bacterial propagation. By limiting their effects to the selected spectrum bacteria, these compounds can treat or prevent specific bacterial infections without disrupting the normal bacterial flora, the patients' microbiome, or causing antibacterial resistance.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: August 30, 2022
    Assignee: TRANA DISCOVERY, INC.
    Inventors: Steven E. Peterson, Samuel P. Yenne, Joseph Christopher Ellis, Richard H. Guenther
  • Publication number: 20210317170
    Abstract: The present disclosure is directed to compositions and methods for targeted drug delivery that comprise a biocompatible framework carrying at least one drug and a viral surface protein, where the viral surface protein mediates entry into a target cell and is attached to an outer surface of the biocompatible framework in the drug carrier.
    Type: Application
    Filed: November 2, 2020
    Publication date: October 14, 2021
    Inventor: Joseph Christopher Ellis
  • Publication number: 20210316002
    Abstract: The present disclosure is directed to compositions and methods for targeted drug delivery that comprise a biocompatible framework carrying at least one drug and a viral surface protein, where the viral surface protein mediates entry into a target cell and is attached to an outer surface of the biocompatible framework in the drug carrier.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 14, 2021
    Inventor: Joseph Christopher Ellis
  • Publication number: 20190024152
    Abstract: Methods are disclosed for identifying antibacterial compounds which inhibit propagation of selected spectrum bacteria, which bacteria use specific tRNA to code for Ala, Met, Ser, or Leu that other bacteria do not use. In one embodiment, the selected spectrum bacteria use GCA to code for Ala, whereas other bacteria use a different codon to code for alanine. The methods involve determining whether putative inhibitors promote or inhibit complex formation between the tRNA and a bacterial ribosome, or between the tRNA and an aminoacyl synthetase. Compounds which promote or inhibit complex formation can disrupt protein production, which bacteria need to propagate. The identified antibacterial compounds can selectively inhibit bacterial propagation. By limiting their effects to the selected spectrum bacteria, these compounds can treat or prevent specific bacterial infections without disrupting the normal bacterial flora, the patients' microbiome, or causing antibacterial resistance.
    Type: Application
    Filed: August 11, 2016
    Publication date: January 24, 2019
    Applicant: TRANA DISCOVERY, INC.
    Inventors: Steven E. PETERSON, Samuel P. YENNE, Joseph Christopher ELLIS, Richard H. GUENTHER